# A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis

> **NCT03101670** · PHASE2 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 131 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** filgotinib
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03101670
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2018-03-12
- **Final completion:** 2018-03-12
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2018-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101670, "A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03101670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*